Skip to main content

Prospective study of epidemiology and prognostic factors in community-acquired pneumonia

Abstract

Of 342 patients with community-acquired pneumonia, 100 were diagnosed etiologically. In these patients, disease epidemiology, prognostic factors, and influence of antibiotic treatment were analyzed prospectively. Fifty-two patients were treated with a broad-spectrum antibiotic (ceftriaxone), and 48 received a medium-spectrum antibiotic (cefuroxime); some patients in each group also received erythromycin.Streptococcus pneumoniae was the most frequently isolated microorganism (43%), followed byChlamydia pneumoniae (21%),Haemophilus influenzae (19%), andMycoplasma pneumoniae (11%). Factors significantly associated with increased mortality were initially critical or poor clinical condition, involvement of two or more lobules, and complications. Prior administration of antibiotics was predictive of penicillin and erythromycin resistance inStreptococcus pneumoniae, but had no effect on the course of the disease. Eight patients died, 89 were cured, and three had recurrences; there was no significant difference in outcome between treatment groups, regardless of whether patients also received erythromycin. Increased knowledge of epidemiological, predictive, and prognostic factors can significantly improve early diagnosis of community-acquired pneumonia and facilitate the choice of appropriate antibiotic treatment, thereby helping to reduce morbidity and mortality.

This is a preview of subscription content, access via your institution.

References

  1. Marrie TJ: Community-acquired pneumonia. Clinical Infectious Diseases 1994, 18: 501–515.

    Google Scholar 

  2. Dorca J: Bacterial respiratory infections and pneumonia. Current Opinion in Infectious Diseases 1990, 3: 176–180.

    Google Scholar 

  3. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor WA, Grayston JT, Pin Wang S, Kholer R, Muder RR, Yee YC, Rihs JD, Vickers RM: New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 1990, 69: 307–315.

    Google Scholar 

  4. Farr BM, Kaiser DL, Harrison BDW, Connolly CK: Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 1989, 44: 1031–1035.

    Google Scholar 

  5. Venkatesan P, MacFarlane JT: Epidemiology and pathogenesis of prevention of pneumonia. Current Opinion in Infectious Diseases 1991, 4: 145–149.

    Google Scholar 

  6. Amsterdam D: The NCCLS susceptibility documents. Antimicrobics Newsletter 1989, 6: 1–7.

    Google Scholar 

  7. McCabe WR, Jackson GG: Gram negative bacteremia. 1. Etiology and ecology. Archives of Internal Medicine 1962, 110: 847–855.

    Google Scholar 

  8. Winston DJ, Murphy W, Young LS, Hewitt WL: Piperacillin therapy for serious bacterial infections. American Journal of Medicine 1980, 69: 255–261.

    Google Scholar 

  9. Harris RL, Musher DM, Bloom K, Gathe J, Rice L, Sugarman B, Williams TW, Young EJ: Manifestations of sepsis. Archives of Internal Medicine 1987, 147: 1895–1906.

    Google Scholar 

  10. Beam TR Jr, Gilbert DN, Kunin CM: General guidelines for the clinical evaluation of anti-infective drug products. Clinical Infectious Diseases 1992, 15, Supplement 1: 5–32.

    Google Scholar 

  11. Marrie TJ, Durant H, Yates L: Community-acquired pneumonia requiring hospitalization: 5 year prospective study. Reviews of Infectious Diseases 1989, 11: 586–599.

    Google Scholar 

  12. Ausina V, Coll P, Sambeat M, Puig J, Condom J, Luquin M, Ballester F, Prats G: Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. European Journal of Clinical Microbiology & Infectious Diseases 1988, 7: 342–347.

    Google Scholar 

  13. Carrillo de Albornoz MM, Pérez de Heredia JH, Sánchez Alvarez J, Tiberio López G, Hernández Palacios R, Rivero Puente A: Epidemiología de las neumonias adquiridas en la comunidad del área de salud 1 de Navarra. Medicina Clinica 1991, 97: 50–52.

    Google Scholar 

  14. Rello J, Quintana E, Ausina V, Net A, Prats G: A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest 1993, 103: 332–335.

    Google Scholar 

  15. Lynch JP: Community-acquired pneumonia: what new trends mean in practice. Journal of Respiratory Diseases 1992, 13: 1619–1643.

    Google Scholar 

  16. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P: Severe community-acquired pneumonia: etiology, epidemiology, and prognosis factors. Chest 1994, 105: 1487–1495.

    Google Scholar 

  17. Lim Y, Shaw DR, Stanley DP, Lumb R, McLennan G: A prospective hospital study of the aetiology of community acquired pneumonia. Medical Journal of Australia 1989, 151: 87–91.

    Google Scholar 

  18. Gaztelurrutia L, Zalacain R, Rubio G, Hernández JL, Urra E, Hernández M, Garea C, Barron J: Actualidad de la penicilina en las neumonias neumocócicas extrahospitalarias. Enfermedades Infecciosas Microbiologia Clínica 1994, 12: 17–20.

    Google Scholar 

  19. Sánchez C, Armengol R, Mir Y, Lite J, Garau J: Neumococos resistentes a la penicilina y uso empírico de penicilinas en el tratamiento de la neumonía aguda extrahospitalaria. Enfermedades Infecciosas Microbiología Clinica 1992, 10: 334–339.

    Google Scholar 

  20. Gómez J, Ruiz Gómez J, Hernandez Cardona JL, Nuñez ML, Canteras M, Valdés M: Antibiotic resistance patterns ofStreptococcus pneumoniae, Haemophilus influenzae, andMoraxella catarrhalis: prospective study in Murcia, Spain, 1983–1992. Chemotherapy 1994, 40: 299–303.

    Google Scholar 

  21. Blasi F, Cosentini R, Legnani D, Denti F, Allegra L: Incidence of community acquired pneumonia caused byChlamydia pneumoniae in Italian patients. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 696–699.

    Google Scholar 

  22. Almirall J, Morato I, Riera F, Verdaguer A, Priu R, Coll P, Vidal J, Murgui L, Vallas F, Catalan F: Incidence of community-acquired pneumonia andChlamydia pneumoniae infection: a prospective multicenter study. European Respiratory Journal 1993, 6: 14–18.

    Google Scholar 

  23. Hammerschlag MR: Antimicrobial susceptibility and therapy of infections caused byChlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 1994, 38: 1873–1878.

    Google Scholar 

  24. Blanquer J, Blanquer R, Borras R, Nauffal D, Morales P, Menéndez R, Subias Y, Herrero L, Redon J, Pascual J: Aetiology of community acquired pneumonia in Valencia, Spain: multicentre prospective study. Thorax 1991, 41: 508–511.

    Google Scholar 

  25. Dronda F, Moreno S, Montilla de Mora P, Gonzalez FJ, Hernández JM, Fortun J, Buzón L: Neumonia porMycoplasma pneumoniae. Enfermedades Infecciosas Microbiología Clínica 1989, 7: 312–315.

    Google Scholar 

  26. Pascual JM, Redón J, Borras R, Vila B, Bertolin V, López Camps V, Belda A, Michavila J, García de Lomas J: Neumonia porLegionella pneumophila. Características clínicas de 52 casos. Medicina Clínica 1987, 89: 489–493.

    Google Scholar 

  27. Farr BM, Sloman AJ, Fisch MJ: Predicting death in patients hospitalized for community-acquired pneumonia. Annals of Internal Medicine 1991, 115: 428–436.

    Google Scholar 

  28. Andrews BE, Bartlett CLR, Connolly CK, Ellis DA, Farr BM, Gooch CD, Harrison BDW, McFarlane JT, Macrae AD, Miller D, Pugh S, Selkon B: Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognosis factors and outcome. Quarterly Journal of Medicine 1987, 62: 195–220.

    Google Scholar 

  29. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A: Severe community-acquired pneumonia: etiology, prognosis, and treatment. American Review of Respiratory Diseases 1990, 142: 369–373.

    Google Scholar 

  30. Gómez J, Baños V, Ruiz Gómez J, Herrero F, Nuñez ML, Canteras M, Valdés M: Clinical significance of pneumococcal bacteremia in a general hospital. A prospective study 1989–1993. Journal of Antimicrobial Chemotherapy 1995, 36: 1021–1030.

    Google Scholar 

  31. Hueston WJ, Schiaffino MA: Antibiotic choice and patients outcome in community-acquired pneumonia. Journal of the American Board of Family Practice 1994, 7: 95–99.

    Google Scholar 

  32. Gómez J, Ruiz Gómez J, Herrero F, Molina Boix M, Baños V, Valdés M: Elección razonada del uso de antibióticos en la práctica clínica. Enfermedades Infecciosas Microbiología Clínica 1993, 11: 214–220.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gómez, J., Baños, V., Gómez, J.R. et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 15, 556–560 (1996). https://doi.org/10.1007/BF01709363

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01709363

Keywords

  • Treatment Group
  • Internal Medicine
  • Pneumonia
  • Prognostic Factor
  • Penicillin